Harnessing the anti-inflammatory potential of palmitoylethanolamide

Drug Discovery Today

Volumn 19, Issue 10, 2014, Pages 1632-1639

  Alhouayek, Mireille ^a   Muccioli, Giulio G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; ENZYME INHIBITOR; FATTY ACID AMIDASE; N ACYLETHANOLAMINE HYDROLYSING ACID AMIDASE; PALMIDROL; PHOSPHOLIPID; UNCLASSIFIED DRUG; ETHANOLAMINE DERIVATIVE; FATTY-ACID AMIDE HYDROLASE; NAAA PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; PALMITIC ACID DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; DEGENERATIVE DISEASE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IN VIVO STUDY; INFLAMMATION; REVIEW; ANIMAL; HUMAN; METABOLISM;

AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ETHANOLAMINES; HUMANS; INFLAMMATION; PALMITIC ACIDS;

EID: 84908619757     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.007     Document Type: Review

References (76)

1. Muccioli, G.G. (2010) Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov. Today 15, 474-483
2. Ueda, N. et al. (2010) N-Acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolysing acid amidase (NAAA). Prog. Lipid Res. 49, 299-315
3. Lo verme, J. et al. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15-19
4. D'Agostino, G. et al. (2009) Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol. 613, 54-59
5. Scuderi, C. and Steardo, L. (2013) Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol. Disord. Drug Targets 12, 62-69
6. Paterniti, I. et al. (2013) Molecular evidence for the involvement of PPAR-delta and PPAR-gamma in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J. Neuroinflamm. 10, 20
7. Esposito G. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-alpha activation, Gut, http://dx.doi.org/10.1136/gutjnl-2013-305005.
8. Facci, L. et al. (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U. S. A. 92, 3376-3380
9. Lambert, D.M. et al. (1999) Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta 1440, 266-274
10. Sugiura, T. et al. (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275, 605-612
11. Calignano, A. et al. (1998) Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281
12. Costa, B. et al. (2002) Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol. 137, 413-420
13. De Filippis, D. et al. (2010) Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol. Res. 61, 321-328
14. De Petrocellis, L. et al. (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506, 253-256
15. Cantarella, G. et al. (2011) Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol. 82, 380-388
16. Franklin, A. et al. (2003) Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 23, 7767-7775
17. Izzo, A.A. et al. (2012) Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br. J. Pharmacol. 166, 1444-1460
18. Solorzano, C. et al. (2009) Selective N-acylethanolamine-hydrolysing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. U. S. A. 106, 20966-20971
19. Zhu, C. et al. (2011) Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol. Pharmacol. 79, 786-792
20. Petrosino, S. et al. (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52, 415-422
21. Jhaveri, M.D. et al. (2008) Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55, 85-93
22. Suarez, J. et al. (2012) Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. PLoS ONE 7, e37729
23. Darmani, N.A. et al. (2005) Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48, 1154-1163
24. Alhouayek, M. and Muccioli, G.G. (2012) The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol. Med. 18, 615-625
25. Baker, D. et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302
26. Witting, A. et al. (2006) Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc. Natl. Acad. Sci. U. S. A. 103, 6362-6367
27. Loria, F. et al. (2008) Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 28, 633-641
28. Walter, L. et al. (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem. 277, 20869-20876
29. Stella, N. and Piomelli, D. (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425, 189-196
30. Romano, B. et al. (2013) The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br. J. Pharmacol. 169, 213-229
31. Leung, D. et al. (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45, 4720-4726
32. Simon, G.M. and Cravatt, B.F. (2010) Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol. Biosyst. 6, 1411-1418
33. Tsuboi, K. et al. (2011) Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolysing phospholipase D-dependent and -independent pathways. Biochim. Biophys. Acta 1811, 565-577
34. Capasso, R. et al. (2005) Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129, 941-951
35. Cravatt, B.F. et al. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U. S. A. 98, 9371-9376
36. Izzo, A.A. et al. (2008) Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med. 86, 89-98
37. Sun, Y.X. et al. (2005) Involvement of N-acylethanolamine-hydrolysing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim. Biophys. Acta 1736, 211-220
38. Muccioli, G.G. and Stella, N. (2008) Microglia produce and hydrolyse palmitoylethanolamide. Neuropharmacology 54, 16-22
39. Mazzari, S. et al. (1996) N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300, 227-236
40. Bettoni, I. et al. (2013) Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol. Disord. Drug Targets 12, 34-44
41. Luongo, L. et al. (2013) Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets 12, 45-54
42. De Filippis, D. et al. (2011) Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol. Pain 7, 3
43. Marchetti, B. and Abbracchio, M.P. (2005) To be or not to be (inflamed): is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol. Sci. 26, 517-525
44. Drouin-Ouellet, J. and Cicchetti, F. (2012) Inflammation and neurodegeneration: the story 'retolled'. Trends Pharmacol. Sci. 33, 542-551
45. Esposito, E. et al. (2012) Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS ONE 7, e41880
46. Scholz, J. and Woolf, C.J. (2007) The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10, 1361-1368
47. D'Agostino, G. et al. (2007) Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J. Pharmacol. Exp. Ther. 322, 1137-1143
48. Genovese, T. et al. (2008) Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J. Pharmacol. Exp. Ther. 326, 12-23
49. Esposito, E. et al. (2011) Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun. 25, 1099-1112
50. Feledziak, M. et al. (2012) Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis. Recent Pat. CNS Drug Discov. 7, 49-70
51. Blankman, J.L. and Cravatt, B.F. (2013) Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65, 849-871
52. Kathuria, S. et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76-81
53. Alexander, J.P. and Cravatt, B.F. (2005) Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem. Biol. 12, 1179-1187
54. Crow, J.A. et al. (2012) Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597. Biochem. Pharmacol. 84, 1215-1222
55. Fegley, D. et al. (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313, 352-358
56. Clapper, J.R. et al. (2010) Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 13, 1265-1270
57. Ahn, K. et al. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16, 411-420
58. Ahn, K. et al. (2011) Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther. 338, 114-124
59. Huggins, J.P. et al. (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153, 1837-1846
60. Ueda, N. et al. (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J. 280, 1874-1894
61. Tsuboi, K. et al. (2004) N-Cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem. J. 379, 99-106
62. Ponzano, S. et al. (2013) Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors. J. Med. Chem. 56, 6917-6934
63. Duranti, A. et al. (2012) N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. J. Med. Chem. 55, 4824-4836
64. Sasso, O. et al. (2013) Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain 154, 350-360
65. Vitale, R. et al. (2014) Synthesis, structure-activity, and structure-stability relationships of 2-substituted-N-(4-oxo-3-oxetanyl) N-acylethanolamine acid amidase (NAAA) inhibitors. ChemMedChem. 9, 323-336
66. West, J.M. et al. (2012) Biochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolysing acid amidase inhibition. PLoS ONE 7, e43877
67. Aviello, G. et al. (2008) Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J. Mol. Med. 86, 413-422
68. Khasabova, I.A. et al. (2012) Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J. Neurosci. 32, 7091-7101
69. Khasabova, I.A. et al. (2012) Peroxisome proliferator-activated receptor alpha mediates acute effects of palmitoylethanolamide on sensory neurons. J. Neurosci. 32, 12735-12743
70. Okine, B.N. et al. (2012) Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br. J. Pharmacol. 167, 627-640
71. Wise, L.E. et al. (2008) Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology 54, 181-188
72. Li, Y. et al. (2012) Design and synthesis of potent N-acylethanolamine-hydrolysing acid amidase (NAAA) inhibitor as anti-inflammatory compounds. PLoS ONE 7, e43023
73. Monsalve, F.A. et al. (2013) Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators. Inflamm. 2013, 549627
74. Fu, J. et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425, 90-93
75. Devchand, P.R. et al. (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384, 39-43
76. Lo verme, J. et al. (2006) Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 319, 1051-1061